Table 1 Patient and tumor characteristics
Characteristic | RTI ≤ 5 days (n = 342) | RTI > 5 days (n = 105) | P-value* |
|---|---|---|---|
| Â | No. of patients (%) | No. of patients (%) | Â |
Age (years) | Â | Â | 0.168 |
  ≤ 50 | 221 (64.6) | 60 (57.1) |  |
  >  50 | 121 (35.4) | 45 (42.9) |  |
Sex | Â | Â | 0.699 |
 Male | 260 (76) | 78 (74.3) |  |
 Female | 82 (24) | 27 (25.7) |  |
Pathology | Â | Â | 0.877 |
 I | 2 (0.6) | 0 (0) |  |
 II | 15 (4.4) | 5 (4.8) |  |
 III | 325 (95) | 100 (95.2) |  |
T stagea | Â | Â | 0.775 |
 T3 | 277 (81) | 87 (82.9) |  |
 T4 | 65 (19) | 18 (17.1) |  |
N stagea | Â | Â | 0.416 |
 N0 | 54 (15.8) | 10 (9.5) |  |
 N1 | 213 (62.3) | 73 (69.5) |  |
 N2 | 57 (16.7) | 17 (16.2) |  |
 N3 | 18 (5.3) | 5 (4.8) |  |
Overall stagea | Â | Â | 0.690 |
 III | 262 (76.6) | 83 (79.0) |  |
 IVA-B | 80 (23.4) | 22 (21.0) |  |
Schedule dose | Â | Â | 0.013 |
 68 Gy/30 F | 197 (57.6) | 46 (43.8) |  |
 70 Gy/33 F | 145 (42.4) | 59 (56.2) |  |